Bone Solutions Inc. appoints orthopedic surgeon, Nancy Lynch, M.D., of Scale Venture Partners to its Scientific Advisory Board

Bone Solutions Inc. (BSI) announced today that it has appointed Nancy Lynch, M.D., to its Scientific Advisory Board, effective immediately. Dr. Lynch is a Principal with Scale Venture Partners, based in Foster City, Calif. “This addition of Dr. Lynch to our SAB represents an important milestone for BSI, in light of Dr. Lynch’s stature as both a distinguished physician and a leading investor in... 

Tags: American Academy of Orthopaedic Surgeons, biodegradable adhesive technology, Bone Solutions Inc., California, Duke University's Fuqua School of Business, Eugene, FDA, Foster City, Graduate School, human applications, Indiana Hand Center, IrishAngels, Management Change, Nancy Lynch, Oregon, product applications, Resident, Scale Venture Partners, spine surgery, Tony Copp, University of Notre Dame, void filler/cement devices, Washington University School of Medicine

Survey Finds that Automated Order Sets Deliver Benefits in Process Improvements, Regulatory Compliance and Patient Safety

Process improvements, regulatory compliance and patient safety were the top three areas in which hospitals “greatly benefited” from the use of order set software, according to the findings of a recent independent national survey conducted on behalf of Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students. Of the hospital managers surveyed whose... 

Tags: Arvind Subramanian, business intelligence, drug reference tools, Emergency, EUR, evidence-based healthcare, FDA, healthcare professionals, important tool, medication errors, Ovid, P&T Committee, pharmaceutical industry, pharmaceutical information providers, Wolters Kluwer, Wolters Kluwer Health, Wolters Kluwer Health Clinical Solutions

When Treating Sleep Disorders Doctors Must Rule Out Other Diagnoses First

Seventy million people in the United States suffer from sleep disorders according to the National Sleep Foundation. About 40 million of these suffer from acute sleep disorders, including circadian rhythm sleep disturbance. Consider Dan, a 23-year old male complaining of insomnia. He can’t fall asleep at night and habitually arrives at work later than his employer’s 8 a.m. starting time.... 

Tags: circadian rhythm sleep disorders, Consider Dan, depression, FDA, Independent Review Organization, insomnia, Lux, medical necessity review services, National Sleep Foundation, obstructive sleep apnea, phototherapy, shift work sleep disorder, Skip Freedman, sleep disorders, Therapies for circadian disorders

Green tea is actually higher in caffeine

Somewhere among the 14 million or so containers in the Ports of Los Angeles and Long Beach, there is one filled with organic tea, the one that one customs broker Joe Estengo III will find today. After clearing customs and FDA inspections, samples from this shipment will be sent to ANRESCO Laboratories in San Francisco. “We send samples to ANRESCO from every new shipment,” explains Judah... 

Tags: analytical services, ANRESCO Laboratories, Boston, Brunswick Laboratories, chemical sciences, Dragon Pearl Tea, FDA, food, headaches, Joe Estengo III, Long Beach, Los Angeles, metabolic and chemical activities, San Francisco

Convincing Results of Solianis’ Multisensor System in Home-Use Trial

Solianis’ multisensor system for non-invasive Continuous Glucose Monitoring is currently being tested by diabetic patients in the home and work environment. 12 patients have completed a 10-day trial aimed at assessing system reliability. Results indicate that the system tracks glucose in home-use settings and is sensitive to hypoglycemic glucose excursions. With this proof of concept Solianis... 

Tags: Barry W. Wilson, Cantonal Bank of Zürich, diabetes, Europe, FDA, invasive devices, Management Change, Mario Stark, Medtronic President International, multisensor technology, non-invasive device, Solianis, Solianis Business Advisory Board, Solianis Monitoring AG

Evotec Announces Phase I Initiation With P2X7 Antagonist

Evotec AG announced today that Phase I clinical studies for its proprietary, small molecule P2X7 receptor antagonist have been initiated. The P2X7 receptor is an ATP-gated ion channel primarily expressed on cells of the immune system and is thought to play an important role in inflammatory processes through the regulation of a number of proinflammatory cytokines. P2X7 receptor antagonism may provide... 

Tags: alzheimer's disease, biotechnology, biotechnology industries, Evotec AG, FDA, insomnia, marketable products, Michael G Kelly, pain, Partnership, Pfizer, Renovis Inc., rheumatoid arthritis, Securities and Exchange Commission, treatment of Alzheimer's disease, treatment of inflammatory diseases, treatment of insomnia

Akorn, Inc. Announces the FDA Approval of Akten(TM) Ophthalmic Gel 3.5%

Akorn, Inc.today announced the FDA approval of NDA 22-221 for Akten™ Ophthalmic Gel 3.5%, a topical, ocular anesthetic formulation. The NDA was filed June 29, 2007 following the results from a randomized, placebo controlled, Phase III clinical trial in 209 subjects who met the primary endpoint in all three dosing arms (p

Tags: Akorn Inc., Alam, Arthur S. Przybyl, Brandon Busbee, cataract, cataract surgery, Decatur, drug product, Elias Reichel, FDA, Illinois, New Business Development, New Jersey, NJ facility, ophthalmic pharmaceuticals, preservative free lidocaine gel product, prospective products, Securities and Exchange Commission, Somerset, sterile specialty pharmaceuticals, surgery

Apieron, Inc. Announces Appointment of Holly McGarraugh as President and Chief Executive Officer

Apieron, Inc. (www.apieron.com) announced today that its Board of Directors has appointed Holly McGarraugh as president and CEO of the company, effective immediately. Ms. McGarraugh replaces Rich Lotti, who resigned to pursue other business interests. “We chose Holly for the CEO position because of her strong commercialization experience,” said Wende Hutton, Apieron Board member and partner... 

Tags: Abbott, Abbott Labs, Acquisition, Alliance, Apieron Inc., asthma, California, Canaan Partners, Cerexa Inc., Chimerix Inc., Connecticut, Dexcom Inc., Diabetes Care, FDA, healthcare, healthcare investments, healthcare team, Holly McGarraugh, in vivo products, India, IPO, Israel, Management Change, medical solutions, Menlo Park, Regenerative medicine, ReVision Optics Inc., Rich Lotti, start-up

Facet Solutions Completes Facet Joint and Disc Replacement Study

Facet Solutions, Inc. today announced the successful completion of a scientific evaluation for a total joint reconstruction in the lumbar spine by Dr. Vijay Goel’s laboratory at the University of Toledo. The study evaluated the combination of Facet Solutions’ ACADIA(TM) Facet Replacement System (AFRS(TM)) with a semi-constrained disc replacement device and then, separately, with a polymeric... 

Tags: ACADIA(TM) technology, anterior motion-sparing devices, De Novo Ventures, disc replacement technologies, Facet Solutions Inc., FDA, investigational device, Marc Peterman, Ontario, Pequot Ventures, polymeric disc replacement device, received venture capital, semi-constrained disc replacement device, spinal stenosis, Spray Venture Partners, surgical devices, Toronto, treatment of facet-related spinal disorders, United States, University of Toledo, Vijay Goel

Columbia Laboratories Reiterates 2008 Year-End Revenue Guidance

Columbia Laboratories, Inc. today announced that, based on preliminary financial projections, the Company reiterates its previously announced 2008 year-end revenue guidance. On March 11, 2008, Columbia indicated that it expects to achieve 2008 revenues in the range of $35 to $40 million. “Although there is a great deal of uncertainty in the global economies, we still expect Columbia to meet its initial... 

Tags: Assisted Reproductive Technology, bioadhesive drug delivery technology, Columbia, Columbia Laboratories Inc., Conference Call, FDA, healthcare, healthcare industry, hypogonadism, pharmaceutical, preterm birth, Robert S. Mills, Securities and Exchange Commission, United States, vaginal lidocaine product

bone solutions inc, male nurse opening in brisbane, conzace drug, royal hospital oman vacancy, job central hospital dammam, mss, conzace multivitamins drug study, washington university school of medicine nursing jobs, drake international philippines